New Evidence Available
Updated Recommendation
A new evidence synthesis was published:2019, WHO consolidated guidelines on drug-resistant tuberculosis treatment
View latest version (2019)Bibliographic information
GuidelineGuidelines for the programmatic management of drug-resistant tuberculosis - 2011 update
Year of Publication2011
Issuing InstitutionWorld Health Organization
Recommendation
Retired
In the treatment of patients with multidrug-resistant tuberculosis (MDR-TB), regimens should include at least pyrazinamide, a fluoroquinolone, a parenteral agent, ethionamide (or prothionamide), and either cycloserine or PAS (p-aminosalicylic acid) if cycloserine cannot be used
Recommended in favor
Conditional
Certainty of evidence
Very low